NEW YORK, Nov 12 (Reuters) - The U.S. Food and Drug Administration can approve new personalized treatments for rare and deadly genetic diseases based on data from a handful of patients, two of the ...

Skin aging manifests as structural degradation, functional decline, and heightened disease susceptibility. Central to this process is the overactivation of the mitogen-activated protein kinase (MAPK) ...

PAS-004 is being tested in a phase 1 trial for MAPK pathway-driven advanced solid tumors, with dosing initiated at 30 mg. The trial is multicenter, open-label, and dose-escalation, assessing safety, ...

1 Department of Obstetrics and Gynecology, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China 2 Department of Obstetrics and Gynecology, First Affiliated Hospital, Heilongjiang ...

Lucas Kloberdanz-Dyck is a writer for Collider. He grew up creating lists, stories, and worlds, which led to his love of anime and video games. He attended Sheridan College where he earned an Honours ...

How can countries leverage digital solutions to build equitable, relevant, and resilient education systems with a positive impact on learning outcomes? Concurrently, digital technologies are ...

Department of Neurosurgery, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, No. 152 Aiguo Road, Nanchang, Jiangxi 330006, China Department of ...

NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...

Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...